| Literature DB >> 24463578 |
Jyh-Ming Jimmy Juang1, Tzu-Pin Lu2, Liang-Chuan Lai3, Chia-Hsiang Hsueh4, Yen-Bin Liu5, Chia-Ti Tsai5, Lian-Yu Lin5, Chih-Chieh Yu5, Juey-Jen Hwang5, Fu-Tien Chiang5, Sherri Shih-Fan Yeh6, Wen-Pin Chen7, Eric Y Chuang8, Ling-Ping Lai5, Jiunn-Lee Lin5.
Abstract
Brugada syndrome (BrS) is an inheritable sudden cardiac death disease mainly caused by SCN5A mutations. Traditional approaches can be costly and time-consuming if all candidate variants need to be validated through in vitro studies. Therefore, we developed a new approach by combining multiple in silico analyses to predict functional and structural changes of candidate SCN5A variants in BrS before conducting in vitro studies. Five SCN5A non-synonymous variants (1651G>A, 1776C>G, 1673A>G, 3269C>T and 3578G>A) were identified in 14 BrS patients using direct DNA sequencing. Several bioinformatics algorithms were applied and predicted that 1651G>A (A551T) and 1776C>G (N592K) were high-risk SCN5A variants (odds ratio 59.59 and 23.93). The results were validated by Mass spectrometry and in vitro electrophysiological assays. We concluded that integrating sequence-based information and secondary protein structures elements may help select highly potential variants in BrS before conducting time-consuming electrophysiological studies and two novel SCN5A mutations were validated.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24463578 PMCID: PMC3902491 DOI: 10.1038/srep03850
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical presentation, electrocardiographic parameters and SCN5A variants of 14 patients with Brugada syndrome
| Number of Patient | Gender | Age (yrs) | Presentation | PR interval | QRS duration | Type of Brugada ECG | Type of |
|---|---|---|---|---|---|---|---|
| M | 52 | SCD | 285 | 114 | Spontaneous Type I | A551T | |
| M | 35 | SCD | 156 | 131 | Spontaneous Type I | N592K | |
| M | 34 | Syncope | 182 | 106 | Drug induced Type I | R1193Q | |
| M | 48 | Severe chest pain and dizziness | 130 | 118 | Drug induced Type I | R1193Q | |
| M | 50 | Seizure | 198 | 95 | Spontaneous Type I | P1090L | |
| F | 24 | Seizure | 207 | 127 | Spontaneous Type I | P1090L | |
| M | 70 | Syncope | 183 | 129 | Spontaneous Type I | P1090L | |
| M | 45 | Syncope | 190 | 98 | Spontaneous Type I | P1090L | |
| M | 24 | SCD | 207 | 127 | Spontaneous Type I | P1090L | |
| M | 40 | SCD | 171 | 85 | Spontaneous Type I | P1090L | |
| M | 38 | Chest tightness and palpitation | 168 | 116 | Spontaneous Type I | H558R | |
| M | 44 | Dizziness | 145 | 121 | Drug induced Type I | H558R | |
| M | 36 | Syncope | 165 | 103 | Spontaneous Type I | H558R | |
| M | 51 | Chest tightness with hypotension | 147 | 115 | Spontaneous Type I | H558R |
SCD: sudden cardiac death; ECG: electrocardiogram.
Figure 1Location of five amino acid differences in the linear topology of the human cardiac sodium channel α- subunit.
Summary of the results of prediction and EP studies of the 5 SCN5A variants in BrS patients
| Functional Change | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt ID (Count) | Exon | cDNA | pfam Domain | SNP number | Allele Freq (CHB) | Allele Freq (CEU) | GERP Score | SIFT | Polyphen-2 | Align-GVGD | Structural Change | EP studies |
| 1 (1) | E12 | c:1651G>A p:A551T | DUF3451 | NA | NA | NA | 3.35 | T | D | Del1 | + | Pathogenic (our study) |
| 2–5 (4) | E12 | c.1673A>G p.H558R | DUF3451 | rs1805124 | 0.866–0.919 | 0.82 | 2.44 | T | B | N1 | Excluded | Neutral |
| 6 (1) | E12 | c.1776C>G p.N592K | DUF3451 | NA | NA | NA | 4.12 | Int | D | Del2 | − | Pathogenic (our study) |
| 7–12 (6) | E18 | c.3269C>T p.P1090L | Na_trans _assoc | rs1805125 | NA | 0.989–1 | −0.553 | Int | D | N2 | − | Neutral (our study and |
| 13–14 (2) | E20 | c.3578G>A p.R1193Q | Na_trans _assoc | rs41261344 | NA | 0.875–1 | 1.58 | Int | B | N1 | + | Pathogenic |
aa: amino acid; B: Benign; BrS: Brugada syndrome; CHB: Han Chinese in Beijing, China; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; D: damaging; Del1: Deleterious 1; Del2: Deleterious 2; EP: electrophysiological; Freq: Frequency; GERP: Genomic Evolutionary Rate Profiling; GVGD, Grantham Variation Grantham Deviation; Int: intolerant; N1: Neutral 1; N2: Neutral 2; PolyPhen-2, Polymorphism phenotyping-2; Pt: Patient; SIFT: Sorting Intolerant From Tolerant; T: tolerant.
aRelative to CCDS46799.1.
Figure 2Prediction of secondary structural variations at sequence alteration sites in Nav1.5.
(A) Probability of disorder in Nav1.5 was estimated by the RONN algorithm. The X-axis represents amino acid residue position. The yellow bars represent the two identified domains, DUF3451 and Na_trans_assoc. (B–F) The Phyre server was utilized to evaluate possible secondary structural changes around the five sequence alteration sites. The upper panel shows predictions for the wild-type sequence, and the lower panel shows predictions for each mutant. The predicted results are shown in three-state forms: alpha helix (red), beta strand (blue), and coil (gray), and they are summarized in the consensus row. The yellow bars indicate regions which were changed after sequence substitution.
Risk predictions of the four SCN5A variants for Brugada syndrome
| Healthy Controls | NHLBI ESP Allele Freq | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Locus | No. of Patient | Het | Homo | WT | Het | Homo | MAF | EPV (95%CI) | Odds Ratio | EuA | AfA | |
| 1651G>A (A551T) | 1 | 0 | 1 | 551 | 0 | 0 | 0 | 100 (64.28–100) | 59.59 | 1.41E-04 | NA | NA |
| 1776C>G (N592K) | 1 | 0 | 1 | 550 | 1 | 0 | 0.001 | 97.46 (61.84–99.83) | 23.93 | 4.33E-04 | NA | NA |
| 3269C>T (P1090L) | 6 | 6 | 0 | 529 | 22 | 0 | 0.020 | 90.68 (80.55–95.54) | 3.35 | 3.08E-08 | 0 | 0.00025 |
| 3578G>A (R1193Q) | 2 | 0 | 2 | 485 | 63 | 3 | 0.063 | 16.15 (0–77.19) | 0.66 | 8.09E-01 | 0.0013 | 0 |
Het: Heterozygote; Homo: Homozygote; MAF: Minor Allele Frequency; WT: Wild type; EPV: Estimated Prediction Value; NHLBI ESP: National Heart, Lung, and Blood Institute Exome Sequencing Project; EuA: European American; AfA: African American; NA: Not available;
aAllelic odds ratio was calculated.
bCochran-Armitage trend test was used.
Figure 3Effect of the mutations on the electrophysiological function of the human cardiac sodium channel.
(A) Representative current traces. Sodium currents were elicited by a family of step pulses for 45 ms from holding potential of −80 mV to +50 mV with an increase of +10 mV at every step. (B) The voltage-current curves of human cardiac sodium currents of wild-type and mutant proteins. Data are represented as mean ± SEM (n = 3 in N592K (1776C>G) and A551T (1651G>A); n = 4 in wild-type (wt) and P1090L (3269C>T)). Asterisks indicate the statistical significance of the difference between wild-type and the indicated mutants (P < 0.05, by On-way ANOVA with Bonferroni post-hoc test at the same testing membrane potentials). (C) The voltage-dependent steady-state activation curves of sodium currents. Currents were converted to conductance and fit to the Boltzmann equation.
The parameters of steady-state activation and inactivation of wild-type and SCN5A variants
| WT | N592K (1776C>G) | A551T (1651G>A) | P1090L (3269C>T) | |
|---|---|---|---|---|
| −36.3 ± 0.2 | −33.1 ± 0.3** | −38.1 ± 0.2** | −36.8 ± 0.3 | |
| 4.1 ± 0.2 | 5.3 ± 0.6 | 3.2 ± 0.2* | 4.5 ± 0.2 | |
| −86.4 ± 0.7 | −85.2 ± 0.9 | −87.8 ± 0.9 | −87.9 ± 0.7 | |
| −7.5 ± 0.6 | −7 ± 0.8 | −7.1 ± 0.8 | −8.6 ± 0.6 |
WT: Wild type; V0.5, act is the half-activation potential and s, act is the slope of the activation curve. V0.5, inact is the half-inactivation potential and s, inact is the slope of the inactivation curve. Data are mean ± SEM and the asterisks indicate the statistical significances by One-way ANOVA with Bonferroni post-hoc test (**P < 0.01; *P < 0.05; n = 4 in wt and 3269C>T and n = 3 in 1776C>G and 1651G>A).
Figure 4Effect of the mutations on the steady-state inactivation of the human cardiac sodium channel.
(A) Representative current traces. The protocol used is shown in the inset. (B) The steady-state inactivation curves of the wild-type and mutant Nav1.5. The typical current traces of wild-type protein were elicited by a brief 25 msec step pulse to −10 mV after a 3 sec prepulse to clamp the sodium channel to a steady-state inactivation status. The current amplitude was normalized to the maximum value elicited at −130 or −140 mV and the normalized curves were fit to the Boltzmann equation.